SCHEMBL13342957

SCHEMBL13342957

COc1ccc(CN(C(=O)OCc2ccccc2)[C@@H](CC(C)C)C(OC)C(=O)O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 2/20 0.44
▸ CTSS P25774 2/20 0.44
▸ CTSK P43235 2/20 0.44
▸ TSHR P16473 2/20 0.43
▸ ATM Q13315 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MMP1 P03956 3/20 0.42
▸ ACHE P22303 2/20 0.42
▸ PPARG P37231 1/20 0.41
▸ PPARA Q07869 1/20 0.41
▸ FABP7 O15540 1/20 0.41
▸ FABP5 Q01469 1/20 0.41
▸ TDP1 Q9NUW8 2/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ PSEN1 P49768 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15209541 0.82 ATM (0.50) TSHRATMALDH1A1LMNAPOLB
SCHEMBL15209538 0.82 ATM (0.50) TSHRATMALDH1A1LMNAPOLB
SCHEMBL15215174 0.80 ACHE (0.47) TSHRATMALDH1A1LMNAPOLB
SCHEMBL15211141 0.80 ACHE (0.47) TSHRATMALDH1A1LMNAPOLB
SCHEMBL15215172 0.79 ACHE (0.48) TSHRATMALDH1A1LMNAPOLB
SCHEMBL15215173 0.74 ACHE (0.43) TSHRATMALDH1A1LMNAPOLB
SCHEMBL15215178 0.73 TSHR (0.43) TSHRATMALDH1A1LMNAPOLB
SCHEMBL389034 0.70 TSHR (0.55) TSHRATMALDH1A1L3MBTL1ACHE
SCHEMBL29563588 0.70 MAPK1 (0.53) TSHRATMALDH1A1LMNAACHE
SCHEMBL20538250 0.70 ALDH1A1 (0.66) CTSLCTSSCTSKALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745650-B2 alpha stereochemistry at the C-9 and C-10 OH positions offers excellent inhibition of cell growth against MDR sensitive cancer cell lines; starting materials are Paclitaxel and Docetaxel; increased biological activity; side effect reduction; solubility; better therapeutic profile; anticancer TAPESTRY PHARMACEUTICALS, INC (US) 2010-06-29 — — US disclosed
Send feedback